MS Speaks
Multiple Sclerosis => TREATMENTS => Topic started by: agate on September 29, 2018, 11:36:07 am
-
It looks as if the proper dosage for the off-label use of rituximab (Rituxan) for MS is open to question due to the occurrence of too many infections. This is from Clinical Neurology News--a report from the CMSC annual meeting in 2018:
https://www.mdedge.com/clinicalneurologynews/article/168533/multiple-sclerosis/serious-complications-linked-rituximab-ms